Updated version 1-Bristol Myers Squibb discloses patient death cases in early cell therapy research
路透社2026/10/23 15:31Additional details provided in paragraphs 3 to 6
Reuters, October 23 - Bristol Myers Squibb (BMY.N) disclosed on Friday that a patient died in an early-stage clinical trial of its experimental CAR-T cell therapy.
The pharmaceutical company's shares fell 2.5% in early trading.
The company stated that a patient with highly active relapsing multiple sclerosis, a central nervous system autoimmune disorder, died from septic pneumonia.
The company said the patient participated in the clinical trial of Bristol Myers Squibb's experimental cell therapy, zolacabtagene autoleucel (abbreviated as zola-cel).
After receiving high-dose chemotherapy, the patient developed septic pneumonia and died the following day, which was 44 days after receiving the CAR-T infusion. The patient exhibited delayed motor symptoms, and treatment with corticosteroids or intravenous immunoglobulin was ineffective.
In September this year, the company said that, in light of Novartis' (NOVN.S) earlier suspension of eight clinical trials of an experimental cell therapy called "rap-cel," it was reviewing safety data "as a precaution" and had voluntarily paused its research on zola-cel (link).
(To assist non-English speakers, Reuters has automated the translation of its reports into several other languages. Due to potential errors in automated translations or the absence of required context, Reuters does not guarantee the accuracy of the automated translation and provides it for readers' convenience only. Reuters accepts no liability for any damage or loss arising from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Western Digital CFO Refutes Claims of Peaking AI Demand: No Signs of Slowdown, Cooling Off Would Actually Help Us Catch Up with Demand Gap
Western Digital's CFO strongly supports AI storage demand, stating that hyperscale cloud providers are continuously expanding capital expenditures and are already discussing supply needs for 2030 to 2031. Although the company’s quarterly results exceeded expectations and profit guidance was raised, capital expenditures more than doubled compared to the same period last year, putting pressure on free cash flow. This has raised concerns in the market about the sustainability of investment returns in AI data centers, causing the stock to close down by about 3% on Friday.
Executives reveal new monetization strategy for Meta AI: Muse is ad-free but charges for enterprise services, and takes a commission on shopping through AI agents
Meta AI chief Alexandr Wang stated that Muse is available to regular users for free and that Meta has no plans to introduce advertisements. Meta plans to offer paid services to enterprises, but specific pricing and launch timeline have not been disclosed. He also mentioned that Meta's proprietary infrastructure, security systems, and data centers provide Muse with a competitive advantage that is difficult for rivals to replicate.
Report: The Trump administration plans to remove some tariffs on Canadian goods to boost the midterm elections
According to media reports, the Trump administration plans to exempt certain Canadian agricultural and forestry products from the 50% tariff, with an announcement as early as this Friday. To maintain the overall scale of tariffs, this tax reduction may be offset by imposing additional tariffs on other Canadian goods. The move is mainly intended to help Maine Senator Susan Collins retain her seat in the midterm elections, while it could also benefit other Republican candidates in trade-dependent states.
VWO ETF Closes Flat
Crypto prices
More
